<DOC>
	<DOCNO>NCT00633776</DOCNO>
	<brief_summary>The purpose study compare effect nebulized formoterol fumarate ( Perforomist ) dry-powder inhaler formoterol fumarate ( Foradil ) . Perforomist solution make fine spray ( use nebulizer ) breathe 10-15 minute . Foradil take single quick , deep inhalation .</brief_summary>
	<brief_title>Perforomist Versus Foradil Evaluated Inspiratory Capacity High Resolution Computed Tomography ( HRCT )</brief_title>
	<detailed_description>Participation require 3 visit 1-5 week . The first visit ( Screening ) help determine subject ' eligibility medical history , physical exam , lung function testing , exercise testing . Those qualify invite back 2 test visit , subject undergo lung function test high-resolution CT scan treatment one study drug . All subject take study drug : randomize Perforomist Test Visit 1 take Foradil Test Visit 2 , vice versa .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Symptomatic subject moderate severe COPD Age great than/equal 40 year History smoking great than/equal 20 packyears cigarettes No history asthma ( opinion investigator ) No COPD exacerbation within past 2 month require oral corticosteroid hospitalization . No continuous oxygen therapy Subjects body mass index le 15 great 38 Patients must without clinically significant illness condition might interfere study , include limited uncontrolled hypertension , cardiovascular disease , cardiac arrhythmia , diabetes , hyperthyroidism , seizure disorder history pheochromocytoma Be use medically acceptable birthcontrol measure female childbearing potential Not pregnant breastfeed Be willing withhold exist short longacting bronchodilator appropriate time period prior test day ( see ) . Use inhale corticosteroid exclusionary , maintain constant level throughout study . Must willing able perform spirometry , slow vital capacity , plethysmography , DLCO , 6 minute walk appropriate instruction . No known allergy contradiction albuterol formoterol prior significant adverse reaction beta agonist . No hypersensitivity milk protein . Bloating gas lactose exclusion . No use betablockers ( selective nonselective ) , phenothiazine ( thioridazine ) , drug may interact formoterol albuterol duration study . Washout great seven halflives drug prior study . No use cardiac antiarrhythmic Class Ia ( e.g. , disopyramide , procainamide , quinidine ) , class III ( e.g. , amiodarone , dofetilide , ibutilide , sotalol ) , terfenadine , astemizole , mizolastine drug potential significantly prolong QT interval . No use nonpotassium spar diuretic unless fix combination potassium spar diuretic . No investigational drug within 30 day No subject affiliate Division Pulmonary , Critical Care Medicine Hospitalists , David Geffen School Medicine Informed consent Postalbuterol FEV1/FVC less low limit normal ( Hankinson ) Postalbuterol FEV1 30 % 60 % predict ( Hankinson ) An increase FEV1 albuterol sulfate HFA least 5 % 50 ml</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Chronic bronchitis</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Perforomist</keyword>
	<keyword>Foradil</keyword>
	<keyword>CT</keyword>
	<keyword>lung function</keyword>
</DOC>